W Jonat
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson J. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol 2013; 24:2543-8.
20.06.2013Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
20.06.2013Ann Oncol 2013; 24:2543-8
Jonat W, Bachelot T, Ruhstaller Thomas, Kuss I, Reimann U, Robertson J F R
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Aapro M, Saad F, Rizzoli R, Paterson A, Monnier A, Lipton A, Jonat W, Hortobagyi G, Hadji P, Gralow J, Gnant M, Dirix L, Crinò L, Costa L, Colomer R, Coleman R, Body J, Abrahamsson P, Thürlimann B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420-32.
01.03.2008Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
01.03.2008Ann Oncol 2008; 19:420-32
Aapro M, Saad F, Rizzoli R, Paterson A H G, Monnier A, Lipton A, Jonat W, Hortobagyi G N, Hadji P, Gralow J, Gnant M, Dirix L, Crinò L, Costa L, Colomer R, Coleman R E, Body J J, Abrahamsson P A, Thürlimann Beat